

( (S (NP-SBJ Genentech Inc.)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the West German distributor)
                          (PP of
                              (NP its heart drug TPA))) 
                  (VP reached
                      (NP a joint marketing agreement)
		      (PP-CLR with
			      (NP (NP a subsidiary)
				  (PP of
				      (NP (NP Hoechst AG)
					  ,
					  (SBAR (WHNP-1 which)
						(S (NP-SBJ *T*-1)
						   (VP makes
						       (NP the rival anti-clotting agent streptokinase)))))))))))) 
     .))
( (S (NP-SBJ The biotechnology concern)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the agreement)
			  (PP between
			      (NP (NP (NP its longtime West German distributor)
				      ,
				      (NP (NP Boehringer-Ingleheim 's)
					  Dr. Karl Thomae G.m.b.H. subsidiary) 
				      ,)
				  and
				  (NP (NP Hoechst 's)
				      Behringwerke subsidiary))))
		  (VP was
                      (NP-PRD an attempt
			      (S (NP-SBJ *)
				 (VP to
				     (VP expand
					 (NP (NP the market)
					     (PP for
						 (NP (NP blood-clot drugs)
						     (PP in
							 (NP general)))))))))))))
     .))
( (S (NP-SBJ A Genentech spokeswoman)
     (VP said
         (SBAR 0
               (S (NP-SBJ the agreement)
                  (VP calls
                      (SBAR for
                            (S (NP-SBJ Hoechst)
                               (VP to
                                   (VP (VP promote
					   (NP-1 TPA)
					   (PP-2 for
						 (NP heart patients)))
				       and
				       (VP (NP=1 streptokinase)
					   (PP-PRP=2 for
						     (NP other clot-reducing purposes)))))))))))
     .))
